Apr 14, 2020
Geert Kersten, CEO, Cel-Sci draws on his history working on cancer immunotherapy to talk about the opportunities for treating the COVID-19 virus by generating the right kind of immune response without additional inflammation. Entering into a partnership with the University of Georgia Center for Vaccines and Immunology, Cel-Sci is using their LEAPS technology to apply their knowledge from work done with the US government on H1N1 to see if they can treat patients with coronavirus.
@CelSciCorp
#COVID19 #Coronavirus #Immunotherapy #TCells